Renal cancer: management
You must score at least 70% in this module to pass. Ensure you have read ‘Renal cancer: management’ before attempting to complete the module.
This module can be taken up to three times. Once you have passed, you can view the correct answers and download a certificate as a record of your learning.
Additional CPD modules are available in the ‘My CPD’ section of your account.
Quiz Summary
0 of 15 Questions completed
Questions:
Information
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
Results
Results
0 of 15 Questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Categories
- Not categorized 0%
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- Current
- Review
- Answered
- Correct
- Incorrect
- Question 1 of 15
1. Question
The incidence of kidney cancers in the UK has:
CorrectIncorrect - Question 2 of 15
2. Question
The number of new cases of renal cancer each year in the UK (2016–2018 average) is estimated at:
CorrectIncorrect - Question 3 of 15
3. Question
What is the most common form of renal cancer?:
CorrectIncorrect - Question 4 of 15
4. Question
What percentage of renal cancers are preventable in the UK?
CorrectIncorrect - Question 5 of 15
5. Question
What percentage of renal cancers are discovered incidentally?
CorrectIncorrect - Question 6 of 15
6. Question
Causes of renal cell carcinoma can either be sporadic or inherited gene alteration (e.g. mutation, deletion, hypermethylation). Inherited gene alteration is estimated to account for:
CorrectIncorrect - Question 7 of 15
7. Question
The International Metastatic RCC Database Consortium (IMDC) risk model is used to guide treatment. Which of the following are IMDC criteria?
CorrectIncorrect - Question 8 of 15
8. Question
Which metastatic clear cell renal cell carcinoma treatment in the first-line setting should not be given in patients with a favourable IMDC risk score (score 0)?
CorrectIncorrect - Question 9 of 15
9. Question
TNM stage I renal cell carcinoma has a five-year survival estimated at:
CorrectIncorrect - Question 10 of 15
10. Question
What percentage of patients with metastatic renal cell carcinoma have an IMDC risk score that puts them in the intermediate or poor-risk groups?
CorrectIncorrect - Question 11 of 15
11. Question
Adverse events with immune checkpoint inhibitors occur in the following timescales?
CorrectIncorrect - Question 12 of 15
12. Question
Severe immune checking inhibitor (ICI) adverse events are treated by:
CorrectIncorrect - Question 13 of 15
13. Question
Oral VEGF TKIs, such as axitinib, cabozantinib, lenvatinib, pazopanib, suntinib and tivozanib, have an estimated fatality rate from adverse events of:
CorrectIncorrect - Question 14 of 15
14. Question
A patient receiving a VEGF TKI is planning surgery and needs to:
CorrectIncorrect - Question 15 of 15
15. Question
The following are all adverse effects of VEGF TKIs, but which is a rare, potentially fatal adverse event?
CorrectIncorrect